Qi Yang, Yu-liang Qin, Bin Deng and Hong-qiang Wang
Qi Yang, Bin Deng, Yu-liang Qin and Hong-qiang Wang
Wei Song, Huai-yuan Liu, Bin Xiang, Hong Hu, Cheng-jiang Wang and Ling-yun Wan
Ning Ma, Xin Li, Hong-bin Wang, Li Gao and Jian-hua Xiao
Introduction: Tiletamine-xylazine-tramadol (XFM) has few side effects and can provide good sedation and analgesia. Adenosine 5’-monophosphate-activated protein kinase (AMPK) can attenuate trigeminal neuralgia. The study aimed to investigate the effects of XFM and its specific antagonist on AMPK in different regions of the brain. Material and Methods: A model of XFM in the rat was established. A total of 72 Sprague Dawley (SD) rats were randomly divided into three equally sized groups: XFM anaesthesia (M group), antagonist (W group), and XFM with antagonist interactive groups (MW group). Eighteen SD rats were in the control group and were injected intraperitoneally with saline (C group). The rats were sacrificed and the cerebral cortex, cerebellum, hippocampus, thalamus, and brain stem were immediately separated, in order to detect AMPKα mRNA expression by quantitative PCR. Results: XFM was able to increase the mRNA expression of AMPKα1 and AMPKα2 in all brain regions, and the antagonist caused the opposite effect, although the effects of XFM could not be completely reversed in some areas. Conclusion: XFM can influence the expression of AMPK in the central nervous system of the rat, which can provide a reference for the future development of anaesthetics for animals.
Jian-Tao Zhang, Jing-Tao Shao, Yun-Feng Liu and Hong-Bin Wang
Ten mixed-breed female dogs were used in the study. Abdominal wall lifting was performed with a sterilised cotton strip. Four portal sites were used to complete gasless laparoscopic ovariohysterectomy (GLOHE) procedures. The proper and suspensor ligament, ovarian pedicle, and broad ligament of the uterus, uterine artery and vein were coagulated using bipolar electrocoagulation. After the uterine body was coagulated and cut, the end of the cervix was ligated with a loop suture. Blood samples were obtained before the surgery, immediately after the procedure, and on 1, 3, and 5 d postoperatively for the determination of interleukin-6 (IL-6) and C-reactive protein (CRP). No significant surgical complications occurred. After gasless laparoscopic ovariohysterectomy, a significantly higher serum IL-6 level was found immediately after the surgery and 1 d postoperatively when compared with the level observed after traditional laparoscopic ovariohysterectomy (LOHE). However, no significant differences were observed in CRP level between GLOHE and LOHE. GLOHE proved to be a safe and feasible procedure in bitches.
Yin Bai-Shuang, Li Gao, Fu Lian-Jun, Fu Ying, Sha Wan-Li, Li Guo-Jiang and Wang Hong-Bin
The aim of this study was to assess whether atipamezole can restrain telazol/xylazine induced expression of c-fos in the rat brain. Rats were injected with a mixture of 13.81 mg/kg telazol and 5.21 mg/kg xylazine, following 10 min later 0.522 mg/kg atipamezole. Thereon, the thalamencephal and cerebral cortex were removed one hour after the last injection. The level of Fos protein was measured in the brain tissue by Westernblot. The results revealed that atipamezole attenuates telazol/xylazine induction of c-fos expression in the thalamencephal and cerebral cortex. The results indicated that atipamezole is able to inhibit telazol/xylazine-induced c-fos expression in the rat brain, thus protecting it from nerve damage.
Xi-Lin Liu, Xiao-Li Feng, Guang-Ming Wang, Bin-Bin Gong, Waqas Ahmad, Nan-Nan Liu, Yuan-Yuan Zhang, Li Yang, Hong-Lin Ren and Shu-Sen Cui
Introduction: The functions and mechanisms of prion proteins (PrPC) are currently unknown, but most experts believe that deformed or pathogenic prion proteins (PrPSc) originate from PrPC, and that there may be plural main sites for the conversion of normal PrPC into PrPSc. In order to better understand the mechanism of PrPC transformation to PrPSc, the most important step is to determine the replacement or substitution site.
Material and Methods: BALB/c mice were challenged with prion RML strain and from 90 days post-challenge (dpc) mice were sacrificed weekly until all of them had been at 160 dpc. The ultra-structure and pathological changes of the brain of experimental mice were observed and recorded by transmission electron microscopy.
Results: There were a large number of pathogen-like particles aggregated in the myelin sheath of the brain nerves, followed by delamination, hyperplasia, swelling, disintegration, phagocytic vacuolation, and other pathological lesions in the myelin sheath. The aggregated particles did not overflow from the myelin in unstained samples. The phenomenon of particle aggregation persisted all through the disease course, and was the earliest observed pathological change.
Conclusion: It was deduced that the myelin sheath and lipid rafts in brain nerves, including axons and dendrites, were the main sites for the conversion of PrPC to PrPSc, and the PrPSc should be formed directly by the conversion of protein conformation without the involvement of nucleic acids.
Wen Xie, Hong Zhao, Yu Chen, Qin Zhang, Wei Lu, Wei Liu, Ai-rong Hu, Han-wei Li, Ping Feng, Ming-sheng Chen, Cun-jin Mei, Xiao-lin Guo, Xiao-hu Zhao, Jiang-bin Wang, Zheng-qin Fan, Jian-he Gan, Qing Xie and Jun Cheng
Obejective Ademetionine 1,4-butanedisulfonate [S-adenosyl-L-methionine (SAMe)/Transmetil®, Abbott] has been available in China for more than 15 years, and it has been shown to reduce serum bilirubin and transaminase levels in viral hepatitis (VH) patients. However, no large-scale studies have focused on the impact of SAMe treatment regimen on reducing the serum total bilirubin (TBil) in VH patients with intrahepatic cholestasis (IHC). The primary purpose of this study was to evaluate the effectiveness of intravenous SAMe (Transmetil®) treatment in reducing the serum TBil by 50%.
Methods This retrospective, multi-center, cross-sectional medical record review involved patients aged ≥18 years. Records of 1 280 hospitalized VH patients at 16 sites diagnosed with IHC who had received intravenous SAMe 1 000 mg or 2 000 mg q.d. for at least 7 days from January 1, 2006 to June 30, 2009, were screened and 905 records were randomly selected.
Results The safety set (SS) included 834 patients and the full analysis set 826 patients. TBil levels after 14 days injection treatment were available for 763 patients. TBil decreased ≥ 50% versus baseline after 14 days treatment in 288 (37.7%) patients (95% CI 34.3%, 41.2%). Twenty-nine non-serious adverse events (non-SAEs) were reported in 19 (2.3%) patients, and 29 SAEs were reported in 10 patients (1.2%). All adverse events (AEs) were considered unrelated to the study drug.
Conclusions This retrospective study shows that intravenous SAMe administration in VH patients with IHC is associated with significant reduction of TBil levels in more than 30% of patients 14 days after treatment initiation.